Showing 1941-1950 of 2530 results for "".
- Rion Aesthetics Initiates Series Ahttps://modernaesthetics.com/news/rion-aesthetics-initiates-series-a/2473241/With the initiation of Series A funding, Rion Aesthetics presents a unique investment opportunity for aesthetic providers. Rion plans on closing the Series A in the second quarter of 2022. Rion, a regenerati
- Evolus Celebrates Third Anniversary of the Launch of Jeuveauhttps://modernaesthetics.com/news/evolus-celebrates-third-anniversary-of-the-launch-of-jeuveau/2473239/Evolus, Inc. is celebrating the three-year anniversary of the launch of its flagship neurotoxin product, Jeuveau (prabotulinumtoxinA-xvfs), the first neurotoxin dedicated exclusively to aesthetics. Jeuveau is used for the temporary improvement in the appearance of moderate to severe ve
- Cynosure Receives $60 Million Follow-on Investment from Clayton, Dubilier & Ricehttps://modernaesthetics.com/news/cynosure-recieves-60-million-follow-on-investment-from-clayton-dubilier-rice/2473237/Cynosure, LLC, received $60 million from lead investor Clayton, Dubilier & Rice. The new capital supports the company's plans to continue investing ahead of strong growth to bring innovation to the market and provide comprehensive treatment solutions to its cust
- CellFX from Pulse Biosciences Shows Durable Effects for Sebaceous Hyperplasia: ASLMS Presentationhttps://modernaesthetics.com/news/cellfx-from-pulse-biosciences-shows-durable-effects-for-sebaceous-hyperplasia-aslms-presentation/2473233/The CellFX® system from Pulse Biosciences, Inc. demonstrates durable efficacy for the clearance of Sebaceous Hyperplasia lesions, according to data presented at the 2022
- R2 Technologies Ships 100 GLACIAL Deviceshttps://modernaesthetics.com/news/r2-technologies-ships-100-glacial-devices/2473224/R2 Technologies Inc. has shipped 100 GLACIAL Rx devices across the globe. To-date customers have delivered more than 15,000 GLACIAL treatment cycles, helping patients reach their skin goals by reducing inflammation and revealing younger looking skin. R2 reached this mileston
- Cutera Invites ASLMS Attendees to Celebrate AviClear Launchhttps://modernaesthetics.com/news/cutera-invites-aslms-attendees-to-celebrate-aviclear-launch/2473222/Cutera is celebrating the launch of AviClear during the ASLMS meeting in San Diego, and meeting attendees are invited to join the festivities. AviClear is the first and only FDA cleared energy-based device for the treatment of mild, moderate, and severe acne, The AviClear laun
- Study: Skin of Color Patients Are Under-represented in Cosmetic Clinical Trialshttps://modernaesthetics.com/news/study-skin-of-color-patients-are-under-represented-in-cosmetic-clinical-trials/2473221/There’s a lack of ethnic/racial diversity in industry-sponsored aesthetic trials, according to new research in the April 2022 issue of Lasers in Surgery and Medicine. Researchers, led by Lisa Akintilo MD, MPH a current PGY-4 dermatology resident at New York
- Happy 20th Birthday Botox Cosmetic!https://modernaesthetics.com/news/happy-20th-birthday-botox-cosmetic/2473218/Allergan Aesthetics’ BOTOX Cosmetic (onabotulinumtoxinA) turns 20 on April 15, 2022. This date marks 20 years since the U.S. Food and Drug Administration (FDA) first approved the product to temporarily improve the look of moderate to severe glabellar lines, located between th
- PatientFi, Allergan Expand Co-marketing Agreementhttps://modernaesthetics.com/news/patientfi-allergan-expand-co-marketing-agreement/2473214/PatientFi® is expanding its co-marketing agreement with Allergan Aesthetics, an AbbVie company, to provide financing options for patients interested in treatments such as BOTOX® Cosmetic (onabotulinumtoxinA), JUVÉDERM®Collection of Fillers, Natrelle® breast i
- Aesthetics Innovation Summit Releases Agendahttps://modernaesthetics.com/news/aesthetics-innovation-summit-releases-agenda/2473211/The